(0.00%) 5 214.00 points
(0.00%) 39 027 points
(0.01%) 18 201 points
(-0.68%) $77.85
(0.14%) $2.21
(-0.02%) $2 323.80
(0.09%) $27.57
(-0.04%) $988.00
(0.13%) $0.931
(0.37%) $10.94
(0.17%) $0.801
(0.01%) $91.45
-4.12% ¥ 163.00
Live Chart Being Loaded With Signals
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan...
Stats | |
---|---|
Dzisiejszy wolumen | 663 500 |
Średni wolumen | 320 136 |
Kapitalizacja rynkowa | 7.47B |
EPS | ¥0 ( 2024-05-07 ) |
Last Dividend | ¥0 ( N/A ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -3.31 |
ATR14 | ¥0.247 (0.15%) |
Wolumen Korelacja
SymBio Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
SymBio Pharmaceuticals Korelacja - Waluta/Towar
SymBio Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | ¥5.59B |
Zysk brutto: | ¥4.41B (78.91 %) |
EPS: | ¥-49.19 |
FY | 2023 |
Przychody: | ¥5.59B |
Zysk brutto: | ¥4.41B (78.91 %) |
EPS: | ¥-49.19 |
FY | 2022 |
Przychody: | ¥10.01B |
Zysk brutto: | ¥7.60B (75.94 %) |
EPS: | ¥30.20 |
FY | 2021 |
Przychody: | ¥8.25B |
Zysk brutto: | ¥5.80B (70.28 %) |
EPS: | ¥53.04 |
Financial Reports:
No articles found.
SymBio Pharmaceuticals
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej